AT-48 A PHASE 1 TRIAL OF CARBOXYAMIDOTRIAZOLE OROTATE (CTO) IN COMBINATION WITH BEVACIZUMAB FOR ADULT PATIENTS WITH RECURRENT MALIGNANT GLIOMA POST-BEVACIZUMAB FAILURE

CTO, an oral inhibitor of non-voltage-dependent calcium signaling, modulates several pathways, including EGFR, MEK, RAS, HDAC, HSP90, WNT/B-catenin, Akt, ERK, VEGF and Bcr-Abl. A recent Phase I safety study (NCT01107522) in advanced solid tumors, including glioblastoma, demonstrated a safe toxicity...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ranjan, Tulika, Peters, katherine B., Vlahovic, Gordana, Watts, Jason, Dutton, Shelley, Boulton, Susan, Lipp, Eric, Herndon, James, Healy, Patrick, Miller, Elizabeth, Friedman, Henry, Karmali, Rashida, Desjardins, Annick
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2014
Matèries:
Adult Clinical Trials
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217827/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.47
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars